🇺🇸 Ferric Carboxymaltose Injection in United States
17 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 17
Most-reported reactions
- Abdominal Pain — 2 reports (11.76%)
- Blood Pressure Decreased — 2 reports (11.76%)
- Fatigue — 2 reports (11.76%)
- Haemoglobin Decreased — 2 reports (11.76%)
- Hypersensitivity — 2 reports (11.76%)
- Nausea — 2 reports (11.76%)
- Vomiting — 2 reports (11.76%)
- Abortion Infected — 1 report (5.88%)
- Alanine Aminotransferase Increased — 1 report (5.88%)
- Anaphylactic Reaction — 1 report (5.88%)
Other Hematology approved in United States
Frequently asked questions
Is Ferric Carboxymaltose Injection approved in United States?
Ferric Carboxymaltose Injection does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Ferric Carboxymaltose Injection in United States?
Sichuan Huiyu Pharmaceutical Co., Ltd is the originator. The local marketing authorisation holder may differ — check the official source linked above.